Literature DB >> 7581946

Test of growth hormone secretion in adults: poor reproducibility of the insulin tolerance test.

H C Hoeck1, P Vestergaard, P E Jakobsen, P Laurberg.   

Abstract

The insulin tolerance test (ITT) is regarded as the most reliable provocative test in the diagnosis of growth hormone (GH) deficiency in adults. In the present study the test was evaluated by investigating the range of GH responses in normal adult males and females and the intra-individual reproducibility of the test. Sixteen healthy non-obese adults, eight males (median age 31.5 years) and eight females (median age 31.8 years) were tested twice with the ITT, with a minimum of 72 h between each test. The females were tested between day 3 and day 10 of their menstrual cycles. Adequate hypoglycemia was achieved in all cases with a median nadir blood glucose of 1.3 mmol/l (range 0.8-2.0). Growth hormone in serum was measured by immunoradiometric assay and low values were confirmed by a different assay. Median peak GH concentration responses to the ITT were: in males 27.9 micrograms/l, range 5.0-71.1 (test 1) and 30.5 micrograms/l, range 7.9-69.5 (test 2); and in females 9.0 micrograms/l, range 4.1-17.9 (test 1) and 8.4 micrograms/l, range 0.09-42.4 (test 2). The rise in GH concentration during the ITT was higher in males than in females. In the males, all stimulated GH values were > or = 5.0 micrograms/l. In the females, four out of 16 tests gave values below 5.0 micrograms/l and in one test the GH value was around the detection limit of the assays. There was poor reproducibility during repeated testing, with no correlation between the results of the two tests. The results did not correlate to the magnitude of the hypoglycemia.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7581946     DOI: 10.1530/eje.0.1330305

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  18 in total

Review 1.  Diagnosis of adult growth hormone deficiency: still a matter of debate.

Authors:  F Camanni
Journal:  J Endocrinol Invest       Date:  2006-02       Impact factor: 4.256

Review 2.  Growth hormone secretagogues as diagnostic tools in disease states.

Authors:  R Baldelli; X L Otero; J P Camiña; O Gualillo; V Popovic; C Dieguez; F F Casanueva
Journal:  Endocrine       Date:  2001-02       Impact factor: 3.633

3.  Different degrees of GH deficiency evidenced by GHRH+arginine test and IGF-I levels in adults with pituritary disease.

Authors:  G Aimaretti; G Corneli; C Di Somma; R Baldelli; V Gasco; S Rovere; G Migliaretti; A Colao; G Tamburrano; G Lombardi; E Ghigo; F Camanni
Journal:  J Endocrinol Invest       Date:  2005-03       Impact factor: 4.256

4.  IGF-I levels reflect hypopituitarism severity in adults with pituitary dysfunction.

Authors:  Amit Tirosh; Yoel Toledano; Hiba Masri-Iraqi; Yoav Eizenberg; Gloria Tzvetov; Dania Hirsch; Carlos Benbassat; Eyal Robenshtok; Ilan Shimon
Journal:  Pituitary       Date:  2016-08       Impact factor: 4.107

5.  Alström syndrome is associated with short stature and reduced GH reserve.

Authors:  S Romano; P Maffei; V Bettini; G Milan; F Favaretto; M Gardiman; J D Marshall; N A Greggio; G B Pozzan; G B Collin; J K Naggert; R Bronson; R Vettor
Journal:  Clin Endocrinol (Oxf)       Date:  2013-03-26       Impact factor: 3.478

Review 6.  Hypopituitarism following radiotherapy.

Authors:  Ken H Darzy; Stephen M Shalet
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

7.  Glucagon stimulation test for the diagnosis of GH deficiency in adults.

Authors:  F L Conceição; A da Costa e Silva; A J Leal Costa; M Vaisman
Journal:  J Endocrinol Invest       Date:  2003-11       Impact factor: 4.256

8.  Short procedure of GHRH plus arginine test in clinical practice.

Authors:  G Aimaretti; S Bellone; C Baffoni; G Cornel; C Origlia; L Di Vito; S Rovere; E Arvat; F Camanni; E Ghigo
Journal:  Pituitary       Date:  2001-08       Impact factor: 4.107

9.  Hexarelin, a synthetic GH-releasing peptide, is a powerful stimulus of GH secretion in pubertal children and in adults but not in prepubertal children and in elderly subjects.

Authors:  J Bellone; E Bartolotta; C Sgattoni; G Aimaretti; E Arvat; S Bellone; R Deghenghi; E Ghigo
Journal:  J Endocrinol Invest       Date:  1998-09       Impact factor: 4.256

10.  Impaired IGF1-GH axis and new therapeutic options in Alström Syndrome patients: a case series.

Authors:  Cristina Maria Mihai; Doina Catrinoiu; Marius Toringhibel; Ramona Mihaela Stoicescu; Negreanu-Pirjol Ticuta; Hancu Anca
Journal:  Cases J       Date:  2009-01-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.